Established Cardiovascular Disease: Rare and Atypical Presentations

Established cardiovascular disease (CVD) here means a patient already diagnosed with coronary artery disease, prior myocardial infarction, or a related ischemic condition. This article is about how a new cardiac event can present in that patient, not about diagnosing CVD for the first time. It covers silent myocardial infarction, vasospastic (Prinzmetal) angina, Kounis syndrome, MINOCA (myocardial infarction with non-obstructive coronary arteries), cardiac syndrome X / microvascular angina, spontaneous coronary artery dissection (SCAD), and Takotsubo cardiomyopathy. None of these are separate diseases from "real" heart disease; they are recognized ways that ischemia or infarction can appear on the surface.

What is established: a meaningful share of myocardial infarctions are never clinically recognized at the time they occur, and are found later only on ECG or cardiac imaging; women, older adults, and people with diabetes are more likely than the general population to present without classic substernal chest pressure; and several distinct clinical syndromes (vasospastic angina, Kounis syndrome, MINOCA, cardiac syndrome X, SCAD, Takotsubo cardiomyopathy) can mimic obstructive coronary disease on symptoms and ECG while requiring a different management approach. These patterns are described in cardiology guideline documents and in the primary literature, and clinicians should treat "atypical" symptoms in a patient with known CVD as equally urgent as classic chest pain, not less urgent.

Why this matters more once CVD is already diagnosed

A common assumption is that a patient who already carries a CAD diagnosis will be triaged quickly for any new cardiac-sounding symptom. In practice the opposite often happens: new fatigue, jaw aching, or hiccups get attributed to something else entirely, partly because the patient and the clinician both anchor on the last diagnosis rather than testing for a new event. The American Heart Association and American College of Cardiology's joint chest pain guideline explicitly states that some patients with acute coronary syndrome, particularly women, older adults, and people with diabetes, present without chest discomfort, and recommends evaluating "anginal equivalents" (jaw pain, neck pain, unexplained fatigue, nausea) with the same urgency as classic chest pressure. That guideline recommendation is the strongest and most current piece of evidence behind this entire article; the numeric estimates below vary across studies and should be read as ranges, not fixed figures.

Who tends to have an atypical course, and why

• Diabetes. Autonomic neuropathy can blunt the pain signal from ischemic myocardium. Some patients with long-standing diabetes and established CAD experience painless ischemia even during a large infarction. The exact proportion reported varies substantially across studies and registries; a specific percentage should not be treated as a fixed rate for any individual patient.
• Older adults. Dyspnea, delirium, new fatigue, or syncope can be the only presenting feature of an acute coronary event in patients in their 80s and beyond, sometimes with no chest discomfort reported at all.
• Women. Studies comparing symptom reporting during acute coronary syndrome consistently find women less likely than men to report classic substernal chest pressure and more likely to report throat tightness, jaw pain, back pain, or fatigue as the dominant complaint. Women with established CVD also carry a disproportionate share of SCAD cases (discussed below).

Silent myocardial infarction

Silent MI describes a confirmed infarction, evidenced by troponin elevation, new Q waves, or scar on imaging, that occurred without a recognized acute clinical event at the time.

Autonomic neuropathy, high pain tolerance, and misattribution of symptoms (assuming heartburn or muscle strain) are the plausible mechanisms most often cited. Estimates of how common silent MI is vary widely by population studied and detection method (resting ECG versus cardiac MRI with late gadolinium enhancement, which is more sensitive to subendocardial scar). Older cohort and registry studies have reported that a substantial minority of infarctions in the general population, and a higher share in people with diabetes, are detected only retrospectively on ECG or imaging. The precise percentages attached to these findings in older secondary summaries should be verified against the primary studies before being quoted as fixed figures.

Detection in practice: a resting 12-lead ECG remains the first-line tool. New Q waves in the inferior leads (II, III, aVF) or anterior leads (V1-V4) in a patient without a known prior event should prompt troponin measurement and cardiology referral, not automatic dismissal as "old finding, no action needed." Cardiac MRI can identify scar that a resting ECG misses. Patients with established CAD and diabetes are reasonable candidates for at least annual ECG monitoring and a lower threshold for further testing if functional capacity declines without an obvious explanation, consistent with general chest-pain guideline practice, though the exact screening interval is a matter of clinical judgment rather than a single universal rule.

Vasospastic (Prinzmetal) angina

Vasospastic angina produces chest pain from focal or diffuse coronary artery spasm rather than fixed atherosclerotic obstruction, and it can coexist with established CAD, which is exactly what makes it confusing on presentation.

The defining clinical pattern is rest pain, most often overnight, sometimes waking the patient from sleep, with transient ST-segment elevation on ECG that resolves within minutes of sublingual nitroglycerin. Recognized triggers include cold exposure, hyperventilation, cocaine use, and certain drugs (5-fluorouracil, ergotamine, triptans). European cardiology guidelines on chronic coronary syndromes classify vasospastic angina as a distinct functional coronary disorder and support provocative testing (intracoronary acetylcholine or ergonovine) when non-invasive testing is unrevealing.

The diagnostic trap in a patient with known CAD: transient ST elevation in someone with documented multi-vessel disease is often assumed to be a new plaque rupture and triggers emergent catheterization, which is the correct default. But if angiography shows no new culprit lesion and the ST changes have already resolved, vasospasm becomes the leading explanation rather than a missed clot. Management centers on calcium channel blockers, with beta-blockers avoided as monotherapy because unopposed alpha-adrenergic tone can worsen spasm; long-acting nitrates are used adjunctively.

MINOCA: infarction without obstructive coronary disease

MINOCA describes patients who meet universal MI criteria (a rise in troponin above the assay's upper reference limit, plus supporting evidence of ischemia) but whose angiogram shows no stenosis above 50% in any major vessel.

The mechanisms behind a MINOCA presentation are genuinely heterogeneous: plaque disruption with spontaneous clot resolution, coronary embolism, coronary spasm, SCAD, Takotsubo cardiomyopathy, and coronary microvascular dysfunction can all produce the same "normal-looking" angiogram despite real myocardial injury. Studies report that MINOCA makes up a meaningful minority of all MI presentations, and that women are represented at a higher rate among MINOCA patients than among patients with obstructive-CAD MI. This is not a benign diagnosis; published cohorts have found a non-trivial rate of major adverse cardiovascular events over the following year, though the exact event rate depends heavily on which underlying mechanism turns out to be responsible.

The American Heart Association's scientific statement on MINOCA outlines a systematic post-angiography workup: cardiac MRI (ideally within about a week, to look for myocarditis, Takotsubo pattern, or an embolic infarct pattern), intravascular imaging (OCT or IVUS) during the index catheterization when feasible, provocative spasm testing, and a hypercoagulable evaluation in younger patients or those without traditional risk factors. Empiric antiplatelet therapy, a statin, and an ACE inhibitor are reasonable while the underlying mechanism is still being worked out, given the overlap with obstructive CAD pathophysiology.

Kounis syndrome

Kounis syndrome is the simultaneous occurrence of an acute allergic or hypersensitivity reaction and an acute coronary syndrome. Mast-cell degranulation releases histamine, platelet-activating factor, and thromboxane A2, which can provoke coronary spasm and destabilize existing plaque.

Three subtypes are described in the literature: Type I occurs in patients with no known CAD, where the allergic reaction alone triggers spasm in angiographically normal or near-normal arteries. Type II occurs in patients with established CAD, where mast-cell mediators trigger plaque erosion or rupture on top of existing disease. Type III involves stent thrombosis triggered by a hypersensitivity reaction to stent components, drug coatings, or contrast media. Antibiotics (particularly beta-lactams), NSAIDs, and contrast agents are the most commonly implicated triggers in published case series.

Clinical clue: the temporal link is what separates this from a routine ACS. Chest pain, ST changes, or troponin elevation within minutes to about two hours of an allergen exposure (a new drug, a food, an insect sting) in a patient with known CVD should raise Kounis syndrome specifically. Management has to address both problems at once: epinephrine for anaphylaxis, titrated carefully because of its own arrhythmogenic potential, alongside standard ACS management (antiplatelet therapy, nitrates for spasm). Beta-blockers are relatively contraindicated in the acute setting because they can blunt the response to epinephrine and worsen spasm.

Cardiac syndrome X and microvascular angina

Cardiac syndrome X describes effort-related angina with objective ischemia on stress testing, but entirely normal-looking epicardial coronary arteries on angiography. The mechanism is coronary microvascular dysfunction, now generally discussed under the broader label "ischemia with non-obstructive coronary artery disease" (INOCA).

This pattern disproportionately affects women. Landmark work from the Women's Ischemia Syndrome Evaluation (WISE) study found that a majority of women referred for angiography because of chest pain had no obstructive CAD, and a substantial share of those women showed objective evidence of microvascular dysfunction on stress testing. Diagnostic criteria proposed in European chronic coronary syndrome guidelines include reduced coronary flow reserve, elevated index of microcirculatory resistance, or a positive microvascular spasm response to acetylcholine testing; PET myocardial perfusion imaging can provide quantitative flow measurements that standard SPECT imaging cannot.

Management generally follows a stepwise approach: calcium channel blockers for a vasospastic component, ACE inhibitors or ARBs to address endothelial dysfunction, and ranolazine has shown symptom benefit in trials of coronary microvascular dysfunction, though the effect size reported varies by trial and should be confirmed against the primary study before being cited as a specific number. Beta-blockers can worsen symptoms in pure microvascular disease without obstructive CAD and are generally used cautiously.

Groups worth a second look: women, older adults, people with diabetes

Each of these groups has a distinct plausible physiologic reason for an atypical course, not just a statistical association.

Women with established CVD. Studies in younger ACS cohorts have found women significantly less likely than men to report classic chest pain and more likely to report throat tightness, jaw pain, or fatigue as the dominant symptom. Women with established CAD also carry a disproportionate share of SCAD cases (see below), which tends to occur in a younger age range than typical atherosclerotic MI.

Older adults. Dyspnea, rather than chest pain, is commonly the dominant presenting symptom in very elderly patients with an acute coronary event. Acute confusion, new fatigue, or syncope can be the only clue. Registry data in Medicare-age populations has found that a meaningful share of the oldest patients present without any chest pain at all; the exact proportion should be verified against the specific registry cited before being used as a precise figure.

People with diabetes. Reduced pain signal transmission from ischemic myocardium, from peripheral and autonomic neuropathy, is the leading explanation. Stress-testing studies in asymptomatic diabetic populations have found inducible ischemia in a meaningful subset of patients who reported no cardiac symptoms at baseline, supporting periodic screening discussions in this group even absent classic angina.

Rare structural and vasomotor presentations worth recognizing

Spontaneous coronary artery dissection (SCAD)

SCAD causes MI through an intramural hematoma that compresses the true arterial lumen, without atherosclerotic plaque rupture. It is frequently missed on standard angiography and often requires high-resolution intravascular imaging (OCT) for a definitive diagnosis. The American Heart Association's scientific statement on SCAD recommends conservative medical management, avoiding PCI when the vessel is not acutely threatened, plus cardiac rehabilitation; recurrence over the following years is a recognized long-term risk that should be discussed with the patient.

Takotsubo (stress) cardiomyopathy

Takotsubo cardiomyopathy produces transient apical ballooning of the left ventricle, typically triggered by a catecholamine surge after emotional or physical stress. It mimics an anterior STEMI, with ST elevation across the precordial leads and acute troponin elevation, but shows no culprit lesion on angiography. Large international registries have found the condition occurs overwhelmingly in postmenopausal women and carries a real in-hospital mortality risk, driven mainly by cardiogenic shock and ventricular arrhythmia, not a "benign mimic" as it is sometimes casually described.

A recent case report described a patient with recurrent Takotsubo cardiomyopathy in which the second episode showed a different (reverse) ballooning pattern from the first (case report, 2026). This illustrates a point relevant to established-CVD patients specifically: a prior Takotsubo diagnosis does not predict that a recurrence will look the same on ECG or echocardiogram, so a clinician should not use a mismatched pattern to rule out recurrence in a patient with that history. This is a single case report, not a settled epidemiologic pattern, and should be treated as illustrative rather than as evidence of a general recurrence rate.

Cardiac amyloidosis presenting as angina-like symptoms

Transthyretin amyloid cardiomyopathy (ATTR-CM) increasingly appears in the differential for patients with angina-like symptoms and heart failure with preserved ejection fraction, particularly in older patients with disproportionate HFpEF, low-voltage ECG despite left ventricular hypertrophy on imaging, and a history of bilateral carpal tunnel syndrome. Studies screening patients undergoing TAVR for aortic stenosis have found unrecognized ATTR-CM in a meaningful minority using bone-scan scintigraphy. Tafamidis is an FDA-approved treatment for ATTR-CM that has shown a mortality benefit in trial data; specific effect sizes and dosing should come from the current FDA label and the primary trial report rather than from secondary summaries.

Diagnostic pitfalls and a safe default

The most common error is attributing atypical symptoms to a comorbidity, GERD, panic disorder, costochondritis, musculoskeletal pain, rather than testing for a new cardiac event. The HEART score (History, ECG, Age, Risk factors, Troponin) is a widely used tool for risk-stratifying chest pain presentations, including atypical variants, and is endorsed for this use in the AHA/ACC chest pain guideline. A low HEART score supports outpatient follow-up; a higher score supports hospital observation with serial troponins.

High-sensitivity troponin assays detect myocardial injury at concentrations well below what older conventional assays could measure, which is why 0/1-hour rule-out protocols have become standard in many emergency departments. The exact negative predictive value reported for any specific rule-out algorithm depends on the validation cohort and assay used, and should be checked against the specific protocol in use locally rather than assumed from a single study.

For a patient with established CAD presenting with any new symptom not fully explained by their known disease, the safe default is a 12-lead ECG promptly on arrival, high-sensitivity troponin at presentation and again about an hour later, and cardiology review before discharge, even if the symptom does not look like classic chest pain. This is the single sentence in this article worth remembering if nothing else is retained.

A bedside decision framework for atypical presentations in known CVD

This framework is a screening aid, not a diagnostic algorithm, and does not replace clinical judgment or a formal risk score such as HEART.

How to use it: a "yes" answer to any row should prompt an ECG and high-sensitivity troponin regardless of how convincing the alternative explanation (allergy, indigestion, anxiety) seems, because in each row the alternative explanation and a real cardiac event can coexist. The framework does not tell a clinician what the diagnosis is; it tells them when to stop assuming the symptom is unrelated to the heart.

Exceptions and limits: this table is not validated as a scored risk tool and has not been tested against outcomes; it is a structured prompt built from the clinical patterns described above, not a substitute for the HEART score or local emergency protocols. It is also not intended for use as a stand-alone tool by patients to self-triage; anyone with new chest discomfort, breathlessness, fainting, or a sense that something is wrong should seek urgent evaluation regardless of whether any row above applies.

What is established, what is plausible, and what is not settled

Established: established cardiovascular disease can present without classic chest pain, particularly in women, older adults, and people with diabetes; several distinct syndromes (vasospastic angina, Kounis syndrome, MINOCA, cardiac syndrome X, SCAD, Takotsubo cardiomyopathy) produce ischemic symptoms or troponin elevation through mechanisms other than plain plaque rupture; and guideline bodies recommend treating anginal equivalents with the same urgency as classic chest pain.

Plausible but not fully quantified here: the exact prevalence figures for silent MI, MINOCA, atypical presentation rates by age and sex, and effect sizes for specific drug treatments (ranolazine in microvascular angina, tafamidis in ATTR-CM) vary across the studies that report them. This draft intentionally avoids restating specific percentages as fixed facts because the underlying citations require verification against the primary papers before they can be presented with confidence.

Not established from the material available here: a validated, outcome-tested bedside screening rule for atypical CVD presentations. The framework above is an original organizing tool built for this article, not a clinically validated instrument, and should not be presented to patients or used in isolation for triage decisions.

When to seek urgent care

New chest discomfort, jaw or arm pain, shortness of breath, fainting, or a sudden allergic reaction accompanied by chest symptoms in a person with known cardiovascular disease warrants emergency evaluation, not a wait-and-see approach, regardless of whether the symptom looks "textbook."

Frequently asked questions